Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in swine renovascular hypertension

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 11, 2009, Pages 1810-1816

  Lin, Jing ^a   Zhu, Xiangyang ^a   Chade, Alejandro R ^a,c   Jordan, Kyra L ^a   Lavi, Ronit ^a,d   Daghini, Elena ^a   Gibson, Matthew E ^a   Guglielmotti, Angelo ^b   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

^b Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Hypertension; Inflammation; MCPs; Microvascular permeability; Remodeling

Indexed keywords

ADENOSINE; BINDARIT; ENDOTHELIN 1; MONOCYTE CHEMOTACTIC PROTEIN; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CARDIOMYOPATHY; CONTROLLED STUDY; DIASTOLE; EX VIVO STUDY; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HYPERTENSION; INFLAMMATION; MICROANGIOPATHY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENOVASCULAR HYPERTENSION; SWINE;

ANALYSIS OF VARIANCE; ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; COLLAGENASES; COLLATERAL CIRCULATION; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 13; MICROCIRCULATION; MONOCYTE CHEMOATTRACTANT PROTEINS; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; PROBABILITY; RANDOM ALLOCATION; SUS SCROFA; SWINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 73949104402     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.190546     Document Type: Article

References (43)

1. Sironi AM, Pingitore A, Ghione S, De Marchi D, Scattini B, Positano V, Muscelli E, Ciociaro D, Lombardi M, Ferrannini E, Gastaldelli A. Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension. 2008;51:282-288.
2. Rodriguez-Porcel M, Herrman J, Chade AR, Krier JD, Breen JF, Lerman A, Lerman LO. Long-term antioxidant intervention improves myocardial microvascular function in experimental hypertension. Hypertension. 2004;43:493-498.
3. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356:830-840.
4. Rodriguez-Porcel M, Zhu XY, Chade AR, Amores-Arriaga B, Caplice NM, Ritman EL, Lerman A, Lerman LO. Functional and structural remodeling of the myocardial microvasculature in early experimental hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H978-H984.
5. Birukova AA, Adyshev D, Gorshkov B, Bokoch GM, Birukov KG, Verin AD. GEF-H1 is involved in agonist-induced human pulmonary endothe-lial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2006;290: L540-L548.
6. Reddy HK, Campbell SE, Janicki JS, Zhou G, Weber KT. Coronary microvascular fluid flux and permeability: influence of angiotensin II, aldosterone, and acute arterial hypertension. J Lab Clin Med. 1993;121: 510-521.
7. Daghini E, Primak AN, Chade AR, Zhu X, Ritman EL, McCollough CH, Lerman LO. Evaluation of porcine myocardial microvascular permeability and fractional vascular volume using 64-slice helical computed tomography (CT). Invest Radiol. 2007;42:274-282.
8. Mohlenkamp S, Lerman LO, Lerman A, Behrenbeck TR, Katusic ZS, Sheedy PF, II, Ritman EL. Minimally invasive evaluation of coronary microvascular function by electron beam computed tomography. Circulation. 2000;102:2411-2416.
9. Capers Qt, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 1997;30:1397-1402.
10. Hilgers KF, Hartner A, Porst M, Mai M, Wittmann M, Hugo C, Ganten D, Geiger H, Veelken R, Mann JF. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int. 2000;58:2408-2419.
11. Molet S, Furukawa K, Maghazechi A, Hamid Q, Giaid A. Chemokine-and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells. J Allergy Clin Immunol. 2000; 105:333-338.
12. Vallbracht KB, Schwimmbeck PL, Seeberg B, Kuhl U, Schultheiss HP. Endothelial dysfunction of peripheral arteries in patients with immunohis-tologically confirmed myocardial inflammation correlates with endothe-lial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies. J Am Coll Cardiol. 2002;40:515-520.
13. Rittig K, Peter A, Baltz KM, Tschritter O, Weigert C, Andreozzi F, Perticone F, Siegel-Axel DI, Stefan N, Fritsche A, Salih HR, Schleicher E, Machicao F, Sesti G, Haring HU, Balletshofer BM. The CCR2 promoter polymorphism T-960A, but not the serum MCP-1 level, is associated with endothelial function in prediabetic individuals. Atherosclerosis. 2008;198:338-346.
14. Sironi M, Guglielmotti A, Polentarutti N, Fioretti F, Milanese C, Romano M, Vigini C, Coletta I, Sozzani S, Bernasconi S, Vecchi A, Pinza M, Mantovani A. A small synthetic molecule capable of preferentially inhibiting the production of the CC chemokine monocyte chemotactic protein-1. Eur Cytokine Netw. 1999;10:437-442.
15. Guglielmotti A, Aquilini L, D'Onofrio E, Rosignoli MT, Milanese C, Pinza M. Bindarit prolongs survival and reduces renal damage in NZB/W lupus mice. Clin Exp Rheumatol. 1998;16:149-154. (Pubitemid 28241568)
16. Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bertani T, Remuzzi G. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 1998; 53:726-734. (Pubitemid 28124289)
17. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, Romero JC. Increased oxidative stress in experimental reno-vascular hypertension. Hypertension. 2001;37:541-546.
18. Lerman LO, Schwartz RS, Grande JP, Sheedy PF, Romero JC. Nonin-vasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol. 1999;10:1455-1465.
19. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholester-olemia. J Am Soc Nephrol. 2005;16:1005-1012.
20. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, Lerman LO, Lerman A. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res. 2007;101:865-874.
21. Zhu X-Y, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant Intervention Attenuates Myocardial Neovascularization in Hypercholesterol-emia. Circulation. 2004;109:2109-2115. (Pubitemid 38620220)
22. Rodriguez-Porcel M, Lerman A, Ritman EL, Wilson SH, Best PJM, Lerman LO. Altered myocardial microvascular 3D architecture in experimental hypercholesterolemia. Circulation. 2000;102:2028-2030.
23. Collins NT, Cummins PM, Colgan OC, Ferguson G, Birney YA, Murphy RP, Meade G, Cahill PA. Cyclic strain-mediated regulation of vascular endothelial occludin and ZO-1: influence on intercellular tight junction assembly and function. Arterioscler Thromb Vasc Biol. 2006;26:62-68.
24. van Nieuw Amerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ, van Hinsbergh VW. Involvement of Rho kinase in endothe-lial barrier maintenance. Arterioscler Thromb Vasc Biol. 2007;27: 2332-2339.
25. Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman LO. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol. 2006; 26:1746-1752.
26. Taylor WR. Hypertensive vascular disease and inflammation: Mechanical and humoral mechanisms. Current Hypertension Reports. 1999;1:96-101.
27. Tucci M, Quatraro C, Frassanito MA, Silvestris F. Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens. 2006;24:1307-1318.
28. Zhu XY, Daghini E, Chade AR, Napoli C, Ritman EL, Lerman A, Lerman LO. Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol. 2007;18:1209-1217.
29. Rodriguez-Porcel M, Lerman A, Herrmann J, Schwartz RS, Sawamura T, Condorelli M, Napoli C, Lerman LO. Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature. Cardiovasc Res. 2003;58:213-221.
30. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-745.
31. Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, Takemiya K, Koga M, Yamamoto T, Imaizumi T. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension. 2004;43:499-503. (Pubitemid 38174161)
32. Ishimaru K, Ueno H, Kagitani S, Takabayashi D, Takata M, Inoue H. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J Cardiovasc Pharmacol. 2007;50:187-194.
33. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res. 2004;94:1203-1210.
34. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54: 2387-2392.
35. Mirolo M, Fabbri M, Sironi M, Vecchi A, Guglielmotti A, Mangano G, Biondi G, Locati M, Mantovani A. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte che-motactic proteins. Eur Cytokine Netw. 2008;19:119-122.
36. Song L, Pachter JS. Monocyte chemoattractant protein-1 alters expression of tight junction-associated proteins in brain microvascular endothelial cells. Microvasc Res. 2004;67:78-89.
37. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction-opening: signaling via Rho and Rho kinase. J Cell Sci. 2003;116:4615-4628.
38. Willott E, Balda MS, Heintzelman M, Jameson B, Anderson JM. Localization and differential expression of two isoforms of the tight junction protein ZO-1. Am J Physiol Cell Physiol. 1992;262:C1119-C1124.
39. Antonios TF. Microvascular rarefaction in hypertension-reversal or over-correction by treatment? Am J Hypertens. 2006;19:484-485.
40. Rodriguez-Porcel M, Lerman A, Best PJ, Krier JD, Napoli C, Lerman LO. Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. J Am Coll Cardiol. 2001;37:608-615.
41. Amann K, Tornig J, Buzello M, Kuhlmann A, Gross ML, Adamczak M, Ritz E. Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int. 2002;62:877-884.
42. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest. 1997;99:1873-1879.
43. Pipinos II, Nypaver TJ, Moshin SK, Careterro OA, Beierwaltes WH. Response to angiotensin inhibition in rats with sustained renovascular hypertension correlates with response to removing renal artery stenosis. J Vasc Surg. 1998;28:167-177.